Sandhya Girish - Senior Director and Senior Scientist, Global Head Oncology, Clinical Pharmacology

Sandhya Girish

Senior Director and Senior Scientist, Global Head Oncology, Clinical Pharmacology

"Working at Genentech is a dream come true; you are in the midst of talented, passionate and extremely bright scientists who constantly motivate and inspire you to accomplish more. I feel fortunate to have the opportunity to implement clinical pharmacology and quantitative strategies and in bringing potential new treatment options to the forefront of patient care."
13
Years at Genentech
44
Publications
13
Awards & Honors

I have more than 20 years of pharmaceutical industry experience in the discovery, development and approval of large and small molecules, including antibody-drug conjugates (ADCs/TDCs) with a focus on quantitative clinical pharmacology, PK/PD, drug metabolism, and translational sciences . As the Senior Director of Oncology, my group currently provides global clinical pharmacology support for all gRED oncology molecules in our portfolio both marketed and those in various stages of clinical development. In addition I serve as a member and Chair of Clinical Pharmacology Leadership Group (CPLG), International Consortium for Innovation and Quality (IQ). During my 12-year tenure at Genentech, I have held varying levels of seniority starting out as a scientist/individual contributor on project teams, senior scientist, pharmacology sub team cross functional leader, clinical pharmacology group leader and Associate Director.

Prior to Genentech, I was a Senior Scientist with Novartis and Genesoft Pharmaceuticals where I provided strategic support in drug discovery and development for oncology and infectious diseases. I have also been a study director and a co-principal investigator for pharmacokinetics and drug metabolism studies at Stanford Research Institute (SRI) International.

Featured Publication

An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.

Clin Pharmacokinet. 2013 Aug;52(8):657-72.

Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S.

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

Curr Drug Metab. 2012 Sep 1;13(7):901-10.

Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, LoRusso PM, Girish S.